Highlights & Basics
- Pityriasis versicolor is a superficial fungal infection of the stratum corneum, due to dimorphic yeasts of the genus Malassezia, leading to hypo- or hyperpigmented macular lesions on seborrheic areas of the trunk.
- Eruption is most common in the summer months in adolescents. Often has a relapsing nature requiring frequent treatment or prophylaxis.
- Primarily a clinical diagnosis that is confirmed by a KOH preparation demonstrating fungal elements with a characteristic spaghetti-and-meatballs appearance indicating the presence of both yeast and short hyphae.
- Easily treated with either topical medications, including zinc pyrithione shampoo, selenium sulfide shampoo, or azole-class topical antifungal creams. More extensive disease may require systemic therapy with antifungal drugs.
- After successful treatment, remind patients that it may take up to 6 weeks before their normal skin pigmentation returns.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Pityriasis versicolor in a light-skinned person
Pityriasis versicolor in a dark-skinned person
Hypopigmented pityriasis versicolor
Pityriasis versicolor in a light-skinned person
Hyperpigmented pityriasis versicolor
Hyperpigmented pityriasis versicolor
KOH and chlorazol black preparation showing short hyphae and spores
Skin biopsy showing short hyphae and yeast
Citations
Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82.[Abstract]
Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33.[Abstract]
Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):287-9.
1. Schwartz RA. Superficial fungal infections. Lancet. 2004 Sep 25-Oct 1;364(9440):1173-82.[Abstract]
2. Crespo-Erchiga V, Florencio VD. Malassezia yeasts and pityriasis versicolor. Curr Opin Infect Dis. 2006 Apr;19(2):139-47.[Abstract]
3. Aljabre SH, Alzayir AA, Abdulghani M, et al. Pigmentary changes of tinea versicolor in dark-skinned patients. Int J Dermatol. 2001 Apr;40(4):273-5.[Abstract]
4. Maymone MBC, Watchmaker JD, Dubiel M, et al. Common skin disorders in pediatric skin of color. J Pediatr Health Care. 2019 Nov-Dec;33(6):727-37.[Abstract][Full Text]
5. Kallini JR, Riaz F, Khachemoune A. Tinea versicolor in dark-skinned individuals. Int J Dermatol. 2014 Feb;53(2):137-41.[Abstract]
6. Pontasch MJ, Kyanko ME, Brodell RT. Tinea versicolor of the face in black children in a temperate region. Cutis. 1989 Jan;43(1):81-4.[Abstract]
7. Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002 Jan;16(1):19-33.[Abstract]
8. Moseley I, Ragi SD, Ouellette S, et al. Tinea versicolour in underrepresented groups: an All of Us database analysis. Skin Health Dis. 2022 Jul 21;3(1):e152.[Abstract][Full Text]
9. Odland GF, Kraning KK. Prevalence, morbidity, and cost of dermatological diseases (editorial). J Invest Dermatol. 1979;73(5):395-401.[Abstract][Full Text]
10. Wyre HW Jr, Johnson WT. Neonatal pityriasis versicolor. Arch Dermatol. 1981 Nov;117(11):752-3.
11. Balestri R, Rech G, Piraccini BM, et al. Pityriasis versicolor during anti-TNF-alpha monoclonal antibody therapy: therapeutic considerations. Mycoses. 2012 Sep;55(5):444-6.[Abstract]
12. Morishita N, Sei Y. Microreview of pityriasis versicolor and Malassezia species. Mycopathologia. 2006 Dec;162(6):373-6.[Abstract]
13. Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004 Nov;51(5):785-98.[Abstract]
14. Gupta AK, Kogan N, Batra R. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother. 2005 Feb;6(2):165-78.[Abstract]
15. Conklin RJ. Common cutaneous disorders in athletes. Sports Med. 1990 Feb;9(2):100-19.[Abstract]
16. Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in culture of Pityrosporum. J Invest Dermatol. 1978 Sep;71(3):205-8.[Abstract]
17. De Luca C, Picardo M, Breathnach A, et al. Lipoperoxidase activity of Pityrosporum: characterisation of by-products and possible role in pityriasis versicolor. Exp Dermatol. 1996 Feb;5(1):49-56.[Abstract]
18. Karaoui R, Bou-Resli M, Alzaid NS, et al. Tinea versicolor: ultrastructural studies on hypopigmented and hyperpigmented skin. Dermatologica. 1981;162(2):69-85.[Abstract]
19. Borgers M, Cauwenbergh G, Van De Ven M, et al. Pityriasis versicolor and Pityrosporum ovale: morphogenetic and ultrastructural considerations. Int J Dermatol. 1987 Nov;26(9):586-9.[Abstract]
20. Thoma W, Kramer HJ, Mayser P. Pityriasis versicolor alba. J Eur Acad Dermatol Venereol. 2005 Mar;19(2):147-52.[Abstract]
21. Allen HB, Charles CR, Johnson BL. Hyperpigmented tinea versicolor. Arch Dermatol. 1976 Aug;112(8):1110-2.[Abstract]
22. Galdari I, El Komy M, Mousa A, et al. Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes. Int J Dermatol. 1992 Apr;31(4):253-6.[Abstract]
23. Dotz WI, Henrickson DM, Yu GS, et al. Tinea versicolor: a light and electron microscopic study of hyerpigmented skin. J Am Acad Dermatol. 1985 Jan;12(1 Pt 1):37-44.[Abstract]
24. Kamalam A, Thambiah AS, Bagavandas M, et al. Mycosis in India: study in Madras. Trans R Soc Trop Med Hyg. 1981;75(1):92-100.[Abstract]
25. Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000 Mar-Apr;1(2):75-80.[Abstract]
26. Hafez M, el-Shamy S. Genetic susceptibility in pityriasis versicolor. Dermatologica. 1985;171(2):86-8.[Abstract]
27. He SM, Du WD, Yang S, et al. The genetic epidemiology of tinea versicolor in China. Mycoses. 2008 Jan;51(1):55-62.[Abstract][Full Text]
28. Stein DH. Superficial fungal infections. Pediatr Clin North Am. 1983 Jun;30(3):545-61.
29. Borelli D, Jacobs PH, Nall L. Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J Am Acad Dermatol. 1991 Aug;25(2 Pt 1):300-5.[Abstract]
30. Lohoue Petmy J, Lando AJ, Kaptue L, et al. Superficial mycoses and HIV infection in Yaounde. J Eur Acad Dermatol Venereol. 2004 May;18(3):301-4.[Abstract]
31. Han A, Calcara DA, Stoecker WV, et al. Evoked scale sign of tinea versicolor. Arch Dermatol. 2009 Sep;145(9):1078.
32. Spence-Shishido A, Carr C, Bonner MY, et al. In vivo Gram staining of tinea versicolor. JAMA Dermatol. 2013 Aug;149(8):991-2.[Full Text]
33. Stamm LV. Pinta: Latin America's forgotten disease? Am J Trop Med Hyg. 2015 Nov;93(5):901-3.[Abstract][Full Text]
34. Yang S, Makredes M, O'Donnell P, et al. A case of Hansen Disease presenting as tinea versicolor. Dermatol Online J. 2013 Apr 15;19(4):7.[Abstract][Full Text]
35. El-Gothamy Z, Abdel-Fattah A, Ghaly AF. Tinea versicolor hypopigmentation: histochemical and therapeutic studies. Int J Dermatol. 1975 Sep;14(7):510-5.[Abstract]
36. Faergemann J. Pityrosporum species as a cause of allergy and infection. Allergy. 1999 May;54(5):413-9.[Full Text]
37. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):287-9.
38. Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59.[Abstract]
39. Mills OH Jr, Kligman AM. Letter: tretinoin in tinea versicolor. Arch Dermatol. 1974 Oct;110(4):638.
40. Shi TW, Ren XK, Yu HX, et al. Roles of adapalene in the treatment of pityriasis versicolor. Dermatology. 2012;224(2):184-8.[Abstract]
41. Wedig JH, Kennedy GL Jr, Jenkins DH, et al. Teratologic evaluation of dermally applied zinc pyrithione on swine. Toxicol Appl Pharmacol. 1976 May;36(2):255-9.
42. Nolen GA, Patrick LF, Dierckman TA. A percutaneous teratology study of zinc pyrithione in rabbits. Toxicol Appl Pharmacol. 1975 Mar;31(3):430-3.[Abstract]
43. Kokturk A, Kaya TI, Ikizoglu G, et al. Efficacy of three short-term regimens of itraconazole in the treatment of pityriasis versicolor. J Dermatolog Treat. 2002 Dec;13(4):185-7.[Abstract]
44. Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg. 2014 Mar-Apr;18(2):79-90.[Abstract]
45. Köse O, Bülent Taştan H, Riza Gür A, et al. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat. 2002 Jun;13(2):77-9.[Abstract]
46. Wahab MA, Ali ME, Rahman MH, et al. Single dose (400 mg) versus 7 day (200 mg) daily dose itraconazole in the treatment of tinea versicolor: a randomized clinical trial. Mymensingh Med J. 2010 Jan;19(1):72-6.[Abstract]
47. US Food and Drug Administration. FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. May 2016 [internet publication].[Full Text]
48. Helou J, Obeid G, Moutran R, et al. Pityriasis versicolor: a case of resistance to treatment. Int J Dermatol. 2014 Feb;53(2):e114-6.
49. Faergemann J, Djarv L. Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutis. 1982 Oct;30(4):542-5;550.
50. Rausch LJ, Jacobs PH. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis. 1984 Nov;34(5):470-1.[Abstract]
51. Faergemann J, Gupta AK, Al Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol. 2002 Jan;138(1):69-73.[Abstract][Full Text]
52. Jung EG, Bohnert E. Mechanism of depigmentation on pityriasis versicolor alba. Arch Dermatol Res. 1976 Oct 27;256(3):333-4.
